ZEISS Medical Technology announced today that the National Medical Products Administration (NMPA) in China has approved the ...
EQS-News: Carl Zeiss Meditec AG / Key word(s): Regulatory Approval ZEISS VISUMAX 800 with SMILE pro software receives ...
The device offers a shortened procedure time and efficient, effective SMILE for patients with myopia, with or without ...
Updated ZEISS femtosecond laser provides refractive surgeons in China with faster treatment, greater flexibility, and significant workflow JENA, Germany and SHANGHAI, Feb. 26, 2025 /PRNewswire/ ...
Aligne Wealth Advisors Investment Management (AWAIM) proactively manages risk and return opportunities as markets evolve. This forward-looking approach recently led to strategic portfolio adjustments ...
Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the fourth quarter and full year ended December 31, 2024. All figures included ...
15d
Despite revenue growth and strategic advancements, Carl Zeiss Meditec AG (CZMWF) faces margin pressures and market uncertainties, particularly in China.
In der Augenmedizin ist der Carl Zeiss Meditec der Weltmarktführer. Die Aktie des MDAX-notierten Medizintechnik-Spezialisten ...
Nevertheless, we were able to post slight growth thanks to the DORC acquisition. The good response to the new products, the approval of our VISUMAX ® 800 refractive laser system for the Chinese market ...
Die Aktien der Carl Zeiss Meditec (ETR: AFXG) AG (ETR:AFX) gaben heute um 6% nach, nachdem das Unternehmen seine Umsatzzahlen für das erste Quartal veröffentlicht hatte. Trotz eines leichten Umsatzans ...
Die gute Resonanz auf die neuen Produkte, die Zulassung unseres refraktiven Lasersystems VISUMAX® 800 im chinesischen Markt sowie die allgemeine Erholung des Auftragseingangs und Auftragsbestands ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback